Loading…

Use of mPEG-PLGA nanoparticles to improve bioactivity and hemocompatibility of streptokinase: In-vitro and in-vivo studies

Streptokinase, a clot-dissolving agent, is widely used in treatment of cardiovascular diseases such as blood clots and deep thrombosis. Streptokinase is a cost-effective drug with a short biological half-life (i.e. 15 to 30 min). In addition, due to its prokaryotic source, the immune response quickl...

Full description

Saved in:
Bibliographic Details
Published in:Materials Science & Engineering C 2021-01, Vol.118, p.111427-111427, Article 111427
Main Authors: Hasanpour, Akram, Esmaeili, Fariba, Hosseini, Hossein, Amani, Amir
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c400t-131e209257b165c19b9e396a6896d7311b52bede3a8975bb88863f7becb509863
cites cdi_FETCH-LOGICAL-c400t-131e209257b165c19b9e396a6896d7311b52bede3a8975bb88863f7becb509863
container_end_page 111427
container_issue
container_start_page 111427
container_title Materials Science & Engineering C
container_volume 118
creator Hasanpour, Akram
Esmaeili, Fariba
Hosseini, Hossein
Amani, Amir
description Streptokinase, a clot-dissolving agent, is widely used in treatment of cardiovascular diseases such as blood clots and deep thrombosis. Streptokinase is a cost-effective drug with a short biological half-life (i.e. 15 to 30 min). In addition, due to its prokaryotic source, the immune response quickly reacts to the drug. Despite these limitations, streptokinase is still the first choice for diseases associated with thrombosis. In this work, streptokinase was encapsulated in mPEG-PLGA nanoparticles to improve its pharmacokinetic properties. The nanoparticles containing the enzyme were prepared by coaxial electrospray and their physicochemical properties, blood compatibility, circulation time and cell toxicity were evaluated. The results showed that the use of mPEG-PLGA nanoparticles to encapsulate the enzyme resulted in prolonged circulation time (up to 120 min) with a slight decrease in its activity. In vivo studies also showed that the nanoparticles containing streptokinase did not have adverse effect on blood biochemistry parameters as well as liver and kidney tissues. As a result, the mPEG-PLGA nanoparticles showed the potential for increasing the biological activity of streptokinase with no important adverse effect. [Display omitted] •Coaxial electrospray was used to prepare nanoparticles of mPEG-PLGA/SK.•These NPs had an acceptable degree of blood compatibility and were not cytotoxic.•The NPs showed to be effective in increasing biological life time of the enzyme.
doi_str_mv 10.1016/j.msec.2020.111427
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2466036717</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0928493120333452</els_id><sourcerecordid>2466036717</sourcerecordid><originalsourceid>FETCH-LOGICAL-c400t-131e209257b165c19b9e396a6896d7311b52bede3a8975bb88863f7becb509863</originalsourceid><addsrcrecordid>eNp9kEtP3DAUha2qqAzQP9AF8rKbDH4kdoy6QQgGpJFgAWvLdu6oniZxsD0j0V9fh4EuWd2HvnOkcxD6QcmSEioutsshgVsywsqD0prJL2hBW8krQhX9ihZEsbaqFafH6CSlLSGi5ZJ9Q8ecs6YhrF6gv88JcNjg4fFmVT2uV1d4NGOYTMze9ZBwDtgPUwx7wNYH47Lf-_yKzdjh3zAEF4bJZG99P3-LT8oRphz--NEkuMT3Y1X4GN4Efj72oTC7zkM6Q0cb0yf4_j5P0fPtzdP1XbV-WN1fX60rVxOSK8opsJKkkZaKxlFlFXAljGiV6CSn1DbMQgfctEo21rZtK_hGWnC2Iarsp-jnwbfEeNlBynrwyUHfmxHCLmlWC0G4kFQWlB1QF0NKETZ6in4w8VVToufO9VbPneu5c33ovIjO3_13doDuv-Sj5AL8OgBQUu49RJ2ch9FB5yO4rLvgP_P_BzoCkyg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2466036717</pqid></control><display><type>article</type><title>Use of mPEG-PLGA nanoparticles to improve bioactivity and hemocompatibility of streptokinase: In-vitro and in-vivo studies</title><source>ScienceDirect Freedom Collection</source><creator>Hasanpour, Akram ; Esmaeili, Fariba ; Hosseini, Hossein ; Amani, Amir</creator><creatorcontrib>Hasanpour, Akram ; Esmaeili, Fariba ; Hosseini, Hossein ; Amani, Amir</creatorcontrib><description>Streptokinase, a clot-dissolving agent, is widely used in treatment of cardiovascular diseases such as blood clots and deep thrombosis. Streptokinase is a cost-effective drug with a short biological half-life (i.e. 15 to 30 min). In addition, due to its prokaryotic source, the immune response quickly reacts to the drug. Despite these limitations, streptokinase is still the first choice for diseases associated with thrombosis. In this work, streptokinase was encapsulated in mPEG-PLGA nanoparticles to improve its pharmacokinetic properties. The nanoparticles containing the enzyme were prepared by coaxial electrospray and their physicochemical properties, blood compatibility, circulation time and cell toxicity were evaluated. The results showed that the use of mPEG-PLGA nanoparticles to encapsulate the enzyme resulted in prolonged circulation time (up to 120 min) with a slight decrease in its activity. In vivo studies also showed that the nanoparticles containing streptokinase did not have adverse effect on blood biochemistry parameters as well as liver and kidney tissues. As a result, the mPEG-PLGA nanoparticles showed the potential for increasing the biological activity of streptokinase with no important adverse effect. [Display omitted] •Coaxial electrospray was used to prepare nanoparticles of mPEG-PLGA/SK.•These NPs had an acceptable degree of blood compatibility and were not cytotoxic.•The NPs showed to be effective in increasing biological life time of the enzyme.</description><identifier>ISSN: 0928-4931</identifier><identifier>EISSN: 1873-0191</identifier><identifier>DOI: 10.1016/j.msec.2020.111427</identifier><identifier>PMID: 33255024</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Blood compatibility ; Coaxial electrospray ; Drug Carriers ; In vivo studies ; mPEG-PLGA nanoparticles ; Nanoparticles ; Particle Size ; Polyesters ; Polyethylene Glycols ; Streptokinase</subject><ispartof>Materials Science &amp; Engineering C, 2021-01, Vol.118, p.111427-111427, Article 111427</ispartof><rights>2020 Elsevier B.V.</rights><rights>Copyright © 2020 Elsevier B.V. All rights reserved.</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c400t-131e209257b165c19b9e396a6896d7311b52bede3a8975bb88863f7becb509863</citedby><cites>FETCH-LOGICAL-c400t-131e209257b165c19b9e396a6896d7311b52bede3a8975bb88863f7becb509863</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33255024$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hasanpour, Akram</creatorcontrib><creatorcontrib>Esmaeili, Fariba</creatorcontrib><creatorcontrib>Hosseini, Hossein</creatorcontrib><creatorcontrib>Amani, Amir</creatorcontrib><title>Use of mPEG-PLGA nanoparticles to improve bioactivity and hemocompatibility of streptokinase: In-vitro and in-vivo studies</title><title>Materials Science &amp; Engineering C</title><addtitle>Mater Sci Eng C Mater Biol Appl</addtitle><description>Streptokinase, a clot-dissolving agent, is widely used in treatment of cardiovascular diseases such as blood clots and deep thrombosis. Streptokinase is a cost-effective drug with a short biological half-life (i.e. 15 to 30 min). In addition, due to its prokaryotic source, the immune response quickly reacts to the drug. Despite these limitations, streptokinase is still the first choice for diseases associated with thrombosis. In this work, streptokinase was encapsulated in mPEG-PLGA nanoparticles to improve its pharmacokinetic properties. The nanoparticles containing the enzyme were prepared by coaxial electrospray and their physicochemical properties, blood compatibility, circulation time and cell toxicity were evaluated. The results showed that the use of mPEG-PLGA nanoparticles to encapsulate the enzyme resulted in prolonged circulation time (up to 120 min) with a slight decrease in its activity. In vivo studies also showed that the nanoparticles containing streptokinase did not have adverse effect on blood biochemistry parameters as well as liver and kidney tissues. As a result, the mPEG-PLGA nanoparticles showed the potential for increasing the biological activity of streptokinase with no important adverse effect. [Display omitted] •Coaxial electrospray was used to prepare nanoparticles of mPEG-PLGA/SK.•These NPs had an acceptable degree of blood compatibility and were not cytotoxic.•The NPs showed to be effective in increasing biological life time of the enzyme.</description><subject>Blood compatibility</subject><subject>Coaxial electrospray</subject><subject>Drug Carriers</subject><subject>In vivo studies</subject><subject>mPEG-PLGA nanoparticles</subject><subject>Nanoparticles</subject><subject>Particle Size</subject><subject>Polyesters</subject><subject>Polyethylene Glycols</subject><subject>Streptokinase</subject><issn>0928-4931</issn><issn>1873-0191</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp9kEtP3DAUha2qqAzQP9AF8rKbDH4kdoy6QQgGpJFgAWvLdu6oniZxsD0j0V9fh4EuWd2HvnOkcxD6QcmSEioutsshgVsywsqD0prJL2hBW8krQhX9ihZEsbaqFafH6CSlLSGi5ZJ9Q8ecs6YhrF6gv88JcNjg4fFmVT2uV1d4NGOYTMze9ZBwDtgPUwx7wNYH47Lf-_yKzdjh3zAEF4bJZG99P3-LT8oRphz--NEkuMT3Y1X4GN4Efj72oTC7zkM6Q0cb0yf4_j5P0fPtzdP1XbV-WN1fX60rVxOSK8opsJKkkZaKxlFlFXAljGiV6CSn1DbMQgfctEo21rZtK_hGWnC2Iarsp-jnwbfEeNlBynrwyUHfmxHCLmlWC0G4kFQWlB1QF0NKETZ6in4w8VVToufO9VbPneu5c33ovIjO3_13doDuv-Sj5AL8OgBQUu49RJ2ch9FB5yO4rLvgP_P_BzoCkyg</recordid><startdate>202101</startdate><enddate>202101</enddate><creator>Hasanpour, Akram</creator><creator>Esmaeili, Fariba</creator><creator>Hosseini, Hossein</creator><creator>Amani, Amir</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202101</creationdate><title>Use of mPEG-PLGA nanoparticles to improve bioactivity and hemocompatibility of streptokinase: In-vitro and in-vivo studies</title><author>Hasanpour, Akram ; Esmaeili, Fariba ; Hosseini, Hossein ; Amani, Amir</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c400t-131e209257b165c19b9e396a6896d7311b52bede3a8975bb88863f7becb509863</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Blood compatibility</topic><topic>Coaxial electrospray</topic><topic>Drug Carriers</topic><topic>In vivo studies</topic><topic>mPEG-PLGA nanoparticles</topic><topic>Nanoparticles</topic><topic>Particle Size</topic><topic>Polyesters</topic><topic>Polyethylene Glycols</topic><topic>Streptokinase</topic><toplevel>online_resources</toplevel><creatorcontrib>Hasanpour, Akram</creatorcontrib><creatorcontrib>Esmaeili, Fariba</creatorcontrib><creatorcontrib>Hosseini, Hossein</creatorcontrib><creatorcontrib>Amani, Amir</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Materials Science &amp; Engineering C</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hasanpour, Akram</au><au>Esmaeili, Fariba</au><au>Hosseini, Hossein</au><au>Amani, Amir</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Use of mPEG-PLGA nanoparticles to improve bioactivity and hemocompatibility of streptokinase: In-vitro and in-vivo studies</atitle><jtitle>Materials Science &amp; Engineering C</jtitle><addtitle>Mater Sci Eng C Mater Biol Appl</addtitle><date>2021-01</date><risdate>2021</risdate><volume>118</volume><spage>111427</spage><epage>111427</epage><pages>111427-111427</pages><artnum>111427</artnum><issn>0928-4931</issn><eissn>1873-0191</eissn><abstract>Streptokinase, a clot-dissolving agent, is widely used in treatment of cardiovascular diseases such as blood clots and deep thrombosis. Streptokinase is a cost-effective drug with a short biological half-life (i.e. 15 to 30 min). In addition, due to its prokaryotic source, the immune response quickly reacts to the drug. Despite these limitations, streptokinase is still the first choice for diseases associated with thrombosis. In this work, streptokinase was encapsulated in mPEG-PLGA nanoparticles to improve its pharmacokinetic properties. The nanoparticles containing the enzyme were prepared by coaxial electrospray and their physicochemical properties, blood compatibility, circulation time and cell toxicity were evaluated. The results showed that the use of mPEG-PLGA nanoparticles to encapsulate the enzyme resulted in prolonged circulation time (up to 120 min) with a slight decrease in its activity. In vivo studies also showed that the nanoparticles containing streptokinase did not have adverse effect on blood biochemistry parameters as well as liver and kidney tissues. As a result, the mPEG-PLGA nanoparticles showed the potential for increasing the biological activity of streptokinase with no important adverse effect. [Display omitted] •Coaxial electrospray was used to prepare nanoparticles of mPEG-PLGA/SK.•These NPs had an acceptable degree of blood compatibility and were not cytotoxic.•The NPs showed to be effective in increasing biological life time of the enzyme.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>33255024</pmid><doi>10.1016/j.msec.2020.111427</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0928-4931
ispartof Materials Science & Engineering C, 2021-01, Vol.118, p.111427-111427, Article 111427
issn 0928-4931
1873-0191
language eng
recordid cdi_proquest_miscellaneous_2466036717
source ScienceDirect Freedom Collection
subjects Blood compatibility
Coaxial electrospray
Drug Carriers
In vivo studies
mPEG-PLGA nanoparticles
Nanoparticles
Particle Size
Polyesters
Polyethylene Glycols
Streptokinase
title Use of mPEG-PLGA nanoparticles to improve bioactivity and hemocompatibility of streptokinase: In-vitro and in-vivo studies
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T17%3A50%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Use%20of%20mPEG-PLGA%20nanoparticles%20to%20improve%20bioactivity%20and%20hemocompatibility%20of%20streptokinase:%20In-vitro%20and%20in-vivo%20studies&rft.jtitle=Materials%20Science%20&%20Engineering%20C&rft.au=Hasanpour,%20Akram&rft.date=2021-01&rft.volume=118&rft.spage=111427&rft.epage=111427&rft.pages=111427-111427&rft.artnum=111427&rft.issn=0928-4931&rft.eissn=1873-0191&rft_id=info:doi/10.1016/j.msec.2020.111427&rft_dat=%3Cproquest_cross%3E2466036717%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c400t-131e209257b165c19b9e396a6896d7311b52bede3a8975bb88863f7becb509863%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2466036717&rft_id=info:pmid/33255024&rfr_iscdi=true